

Supplementary Table 6. Antithrombotics at one year after discharge by proportion of days covered

Antithrombotics	Value
Overall (n=9,540)	
No treatment	2,565 (26.9)
ASA mono	1,872 (19.6)
Other AP mono	3,762 (39.4)
AP dual or above	132 (1.4)
AC without AP	991 (10.4)
AC with AP	218 (2.3)
No treatment at discharge (n=350)	
No treatment	131 (37.4)
ASA mono	62 (17.7)
Other AP mono	112 (32.0)
AP dual or above	2 (0.6)
AC without AP	39 (11.1)
AC with AP	4 (1.1)
ASA mono at discharge (n=3,632)	
No treatment	921 (25.4)
ASA mono	1,485 (40.9)
Other AP mono	1,119 (30.8)
AP dual or above	18 (0.5)
AC without AP	60 (1.7)
AC with AP	29 (0.8)
Other AP mono at discharge (n=694)	
No treatment	194 (28.0)
ASA mono	35 (5.0)
Other AP mono	445 (64.1)
AP dual or above	2 (0.3)
AC without AP	13 (1.9)
AC with AP	5 (0.7)
AP dual or above at discharge (n=3,034)	
No treatment	758 (25.0)
ASA mono	207 (6.8)
Other AP mono	1,921 (63.3)
AP dual or above	102 (3.4)
AC without AP	39 (1.3)
AC with AP	7 (0.2)
AC without AP at discharge (n=1,405)	
No treatment	436 (31.0)
ASA mono	43 (3.1)
Other AP mono	97 (6.9)
AP dual or above	6 (0.4)
AC without AP	753 (53.6)
AC with AP	70 (5.0)

Supplementary Table 6. Continued

Antithrombotics	Value
AC with AP at discharge (n=425)	
No treatment	125 (29.4)
ASA mono	40 (9.4)
Other AP mono	68 (16.0)
AP dual or above	2 (0.5)
AC without AP	87 (20.5)
AC with AP	103 (24.2)

ASA, aspirin; AP, antiplatelets; AC, anticoagulants.